Pierre Fabre Group and partner Array Biopharma Inc. are hoping for approvals on both sides of the Atlantic in the near future for their encorafenib and binimetinib combination treatment for melanoma, boosted by more positive data that have just been presented at the American Society of Clinical Oncology annual meeting in Chicago.
The companies announced updated results from the Phase III COLUMBUS trial in BRAF-mutant advanced melanoma which showed median overall survival...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

